Inactive Instrument

Aeolus Pharmaceuticals, Inc. Stock price OTC Bulletin Board

Equities

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD 0.00% Intraday chart for Aeolus Pharmaceuticals, Inc.
Sales 2015 3.11M Sales 2016 2.08M Capitalization 28.9M
Net income 2015 -2M Net income 2016 -3M EV / Sales 2015 10.8 x
Net Debt 2015 908K Net cash position 2016 3.16M EV / Sales 2016 12.4 x
P/E ratio 2015
-12 x
P/E ratio 2016
-4.67 x
Employees -
Yield 2015 *
-
Yield 2016
-
Free-Float 100%
More Fundamentals * Assessed data
Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended June 30, 2017 CI
Aeolus Pharmaceuticals, Inc. Announces Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event CI
Aeolus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2017 CI
Aeolus Pharmaceuticals, Inc. Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2016 CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2016 CI
Aeolus Pharmaceuticals Inc. Announces Unaudited Consolidated Results for the Second Quarter and Six Months Ended March 31, 2016 CI
Aeolus Pharmaceuticals Inc. Announces Removal of FDA Clinical Hold on AEOL 10150 CI
Aeolus Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2015 CI
Aeolus Pharmaceuticals Enters into Definitive Agreements to Raise Gross Proceeds of $6.75 Million in Private Placement Financing CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2015 CI
Aeolus Pharmaceuticals Inc. announced that it has received $6.75 million in funding from BVF Partners LP and other investors. CI
Aeolus Pharmaceuticals Inc. announced that it has received $1 million in funding from BVF Partners LP. CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015 CI
Barda Exercises $3 Million in Additional Contract Funding for Development of Aeol 10150 as Treatment for Acute Radiation Syndrome CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 05-05-31
Chairman 54 04-04-29
Members of the board TitleAgeSince
Chairman 54 04-04-29
Director/Board Member 67 13-05-07
Director/Board Member 54 13-05-07
More insiders
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.
More about the company
  1. Stock
  2. Equities
  3. Stock Aeolus Pharmaceuticals, Inc.
  4. Stock Aeolus Pharmaceuticals, Inc. - OTC Bulletin Board